Intermountain Health Care, Inc.
intermountainhealth.orgTotal trials
118
Active
20
Phase 3
7
Total enrollment
1,654,759
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Antibiotic Monotherapy | — | — | — | — | — | 1 | |
| Combination Antibiotic Therapy | — | — | — | — | — | 1 | |
| Vasopressin | — | — | — | — | — | 1 | |
| Coronary Artery Calcium Screening and Statin Treatment | — | — | — | — | — | 1 |
Next readouts
- 2026-04-06
- 2026-07
- 2029-01
Top conditions
- Sepsis6
- Coronary Artery Disease5
- Atrial Fibrillation5
- Heart Failure5
- Deep Vein Thrombosis5
- Septic Shock5
- Carbon Monoxide Poisoning4
- Venous Thromboembolism4
Frequently asked questions about Intermountain Health Care, Inc.
- How many clinical trials does Intermountain Health Care, Inc. have on ClinicalTrials.gov?
- Intermountain Health Care, Inc. is listed as the lead sponsor on 118 clinical trials in ClinicalTrials.gov, 20 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Intermountain Health Care, Inc.'s trials are in Phase 3?
- 7 of Intermountain Health Care, Inc.'s trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does Intermountain Health Care, Inc. focus on?
- Intermountain Health Care, Inc.'s most-studied conditions on ClinicalTrials.gov are Sepsis, Coronary Artery Disease, Atrial Fibrillation, Heart Failure, Deep Vein Thrombosis.
- When are Intermountain Health Care, Inc.'s next clinical trial readouts?
- Intermountain Health Care, Inc. has 3 upcoming primary-completion readouts tracked here; the soonest is “Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events”, expected around 2026-04-06.